Visit of the Minister of reform and innovation in the Public Administration, Luigi Nicolais, to the Kedrion plant in Sant’Antimo (Naples)
The Minister of Reform and Innovation in the Public Administration, Luigi Nicolais, recently visited the Kedrion plant for the production of plasma-derived products in Sant’Antimo, near Naples. Kedrion Group, specialising in the production and distribution of pharmaceutical products derived from plasma proteins, has a total of three production plants: in addition to the one in
Paolo Marcucci has joined PPTA’s Global Board of Directors
Paolo Marcucci, President and CEO of Kedrion, has joined the Global Board of Directors of the Plasma Protein Therapeutics Association (PPTA). “We are excited that Mr. Marcucci is joining the Global Board of Directors” said Jan M. Bult, PPTA’s President. “Paolo Marcucci understands the many challenges confronting our industry and the patients we serve. He
European GMP, current issues and future developments: Kedrion in the organising committee of the EMA / PDA Joint Conference
Kedrion (Italy) is the only company working in the plasma derivatives industry which is sitting on the organising committee of the EMEA/PDA (Parenteral Drug Association) Joint Conference. The company appointed Claudia Nardini, in charge of Industrial Development and Research for the company and deputy president of the Italian chapter of the PDA, as its delegate;
Production of plasma-derived products to highest international quality standards: Kedrion technology for the new Moscow plant
Kedrion embarks on its second technology transfer to Russia following the one in Kirov, by signing an agreement in Moscow for the development of a plasma-derivatives production plant to the highest international quality, safety and efficiency standards. The agreement signed between Kedrion, the Dutch company BTI and the Moscow Government covers both the engineering operations
Kedrion buys a production plant in Hungary from Teva Pharmaceutical Industries Ltd
Kedrion SpA has bought yesterday from Teva Pharmaceutical Industries Ltd (a leading global pharmaceutical company) 100% of the shares in Human Bioplazma Manufacturing and Trading Ltd, a company established under the Hungarian law and based in Gödöllo (Budapest). Kedrion thus acquires a manpower of 127 employees, a fractionation and production plant with a productive capacity
Kedrion stakes on “vertical integration”, two agreements signed to buy four plasma collection centres in the USA and Germany
Kedrion has recently finalised two important agreements for the purchase of four plasma collection centres, two in the United States (Florida and Alabama) and two in Germany (Bavaria). The agreement to buy the two US centres, Pensacola (Florida) and Mobile (Alabama), has been signed with Life Therapeutics, a leader in plasma collection for therapeutic and
New method for purifying plasma proteins used to treat Haemophilia A and von Willerbrand disease
Increased availability of Factor VIII and von Willebrand Factor (vWF) using a new chromatography method for purifying Factor VIII and vWF concentrates that can be transferred to an industrial scale: is the result achieved by researchers in Kedrion. This is a particularly effective technique which makes it possible to purify almost double the quantity of
Human plasminogen acknowledged as Orphan Drug
The European Commission, following the positive opinion of the European Medicines Agency (EMEA), has granted the designation of orphan drug to Human Plasminogen, made by Kedrion, in the form of eye drops used for the treatment of ligneous conjunctivitis. Ligneous conjunctivitis is a rare form of conjunctivitis which may lead to blindness and is characterized
EMAS registration for Kedrion: the company’s environmental policy reinforced
Kedrion SpA, specialized in the production of plasma–derived products, is one of the five Italian pharmaceutical companies which got EMAS registration. The company has joined an “Environmental Programme” and has thereby assumed specific environmental policy commitments. At the same time, it has drawn up an “Environmental Statement” which – in terms of regulation CE 761/2001
Research project for developing a new plasma derivative for the treatment of Hepatitis C
For the first time in Europe, a project is currently underway in Naples to develop an anti-infective product for Hepatitis C, containing neutralising immunoglobulins directed against specific viral antigens. With the western market estimated at $400 million ($200 million in the United States alone and about $40 million in Italy), it should guarantee a better
